SCHEMBL13659749

SCHEMBL13659749

CC(C)c1ccc(-c2cc(N)on2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ BLM P54132 1/20 0.39
▸ GAA P10253 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ CHRNA7 P36544 1/20 0.32
▸ DGAT1 O75907 1/20 0.32
▸ NPC1 O15118 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ SCN4A P35499 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PRKDC P78527 2/20 0.31
▸ ATM Q13315 2/20 0.31
▸ ATR Q13535 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13602061 0.78 CCR1 (0.46) MAPTHTTCHRNA7NPC1RAB9A
SCHEMBL13662717 0.78 CCR1 (0.57) ALDH1A1MAPTKDM4EBLMNPC1
SCHEMBL13659772 0.76 NPC1 (0.33) ALDH1A1MAPTKDM4EGAAALOX12
SCHEMBL16826030 0.75 KDM4E (0.42) ALDH1A1MAPTKDM4EBLMNPC1
SCHEMBL13659757 0.73 DHFR (0.35) ALDH1A1MAPTKDM4ECHRNA7DGAT1
SCHEMBL13659765 0.73 HTT (0.42) MAPTHTTNPC1RAB9ASMN1; SMN2
SCHEMBL13659756 0.71 CYP1A2 (0.35) KDM4ECHRNA7NPC1RAB9ACCR1
SCHEMBL22926102 0.71 NPSR1 (0.42) ALDH1A1MAPTKDM4EBLMSMN1; SMN2
SCHEMBL13659760 0.71 LTA4H (0.35) ALDH1A1MAPTKDM4ECHRNA7DGAT1
SCHEMBL6191875 0.70 CYP11B1 (0.42) MAPTNPC1RAB9AATMATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203435-B1 6, 11-BRIDGED BIARYL MACROLIDES ENANTA PHARM INC (US) 2018-07-18 — — EP disclosed
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2014-07-03 — — US disclosed
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2013-06-27 — — US disclosed
US-8354383-B2 6,11-bridged biaryl macrolides ENANTA PHARMACEUTICALS, INC. (US) 2013-01-15 — — US disclosed
US-20090264380-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
US-20090264380-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
WO-2009075923-A2 6, 11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2009-06-18 — — WO disclosed
US-20090118506-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20090118506-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ALDH1A1 1310/4885MAPT 3727/4885KDM4E 1874/4885
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ALDH1A1 1310/4885MAPT 3727/4885KDM4E 1874/4885
US-20090118506-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ALDH1A1 1128/4885MAPT 3681/4885KDM4E 1917/4885
US-20090264380-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 ALDH1A1 1310/4885MAPT 3727/4885KDM4E 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback